Relay Therapeutics/$RLAY
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Relay Therapeutics
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
- Ticker
- $RLAY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 202
- Headquarters
- Cambridge, United States
- Website
- www.relaytx.com
RLAY Metrics
BasicAdvanced
$3.8B
-
-$1.57
1.70
-
Price and volume
Market cap
$3.8B
Beta
1.7
52-week high
$21.27
52-week low
$5.85
Average daily volume
3.4M
Financial strength
Current ratio
18.268
Quick ratio
17.93
Long term debt to equity
0.03
Total debt to equity
0.034
Profitability
EBITDA (TTM)
-308.224
Gross margin (TTM)
-2,497.55%
Net profit margin (TTM)
-2,763.64%
Operating margin (TTM)
-2,999.37%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-22.88%
Return on equity (TTM)
-36.77%
Valuation
Price to revenue (TTM)
306.428
Price to book
4.27
Price to tangible book (TTM)
4.27
Price to free cash flow (TTM)
-14.945
Free cash flow yield (TTM)
-6.69%
Free cash flow per share (TTM)
-1.165
Growth
Revenue change (TTM)
23.88%
Earnings per share change (TTM)
-18.31%
3-year revenue growth (CAGR)
122.31%
3-year earnings per share growth (CAGR)
-18.50%
What the Analysts think about RLAY
Analyst ratings (Buy, Hold, Sell) for Relay Therapeutics stock.
Analyst projections of the future price of Relay Therapeutics stock.
Bulls say / Bears say
Relay reported 11-month progression-free survival at its 400 mg twice-daily dose in Phase 1/2 second-line breast-cancer data, compared with 5.5 months for capivasertib in the company’s comparison. If the result holds in the randomised Phase 3 trial, zovegalisib could offer a meaningful efficacy advantage. (StockAnalysis, Seeking Alpha)
In a heavily pre-treated breast-cancer group, the zovegalisib, atirmociclib and fulvestrant combination produced a 44% response rate, with tumour shrinkage in 85% of evaluable patients. Relay plans to develop the combination in frontline disease, opening another potential use for its lead drug. (GlobeNewswire)
Early data in vascular anomalies showed a volumetric response in 60% of patients at 12 weeks, while nearly all patients reported symptom improvement. This could extend zovegalisib’s opportunity beyond cancer into a distinct group of rare disorders. (Relay Therapeutics)
The reported 11-month progression-free survival comes from Phase 1/2 data, not a completed randomised comparison. Relay says similar trials typically take 30–36 months to enrol, so confirmation of the result may take time and could differ from the early findings. (StockAnalysis)
The frontline triplet result is preliminary: the 44% response rate was based on 34 patients with measurable disease, and median progression-free survival could not yet be estimated. The response data therefore do not establish how long the benefit lasts in frontline treatment. (GlobeNewswire)
Relay used $105.2 million in operating cash in the first half of 2026, and its cash balance rose to $911 million largely after a May equity offering. Further fundraising to support development could dilute existing shareholders. (StockTitan, Relay Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2026.
RLAY Financial Performance
Revenues and expenses
RLAY Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing RLAY
AllUSDEURGBP
Fund name | Fund size | $RLAY weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.30% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.30% |
iShares Healthcare Innovation£DRDR | £1B | 0.30% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.27% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.27% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.